• 1
    Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Eurosida Study Group. Lancet 1998; 352: 17251730.
  • 2
    Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus syndrome. N Engl J Med 1998; 338: 853860.
  • 3
    Mouton Y, Alfandari S, Valete M et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. Federation National des Centers de Lutte contre le SIDA. AIDS 1997; 11: F101F105.
  • 4
    Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. J Am Med Assoc 1996; 276: 19551956.
  • 5
    Park-Wyllie Scalera A, Tseng A, Rourke S. High rate of discontinuation of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support? Correspondence. AIDS 2002; 16: 10841086.
  • 6
    Idoko JA, Akinsete L, Abalaka AD et al. A multicenter study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med 2002; 21: 8386.
  • 7
    Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63F70.
  • 8
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51F58.
  • 9
    Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700705.
  • 10
    Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160: 20502056.
  • 11
    Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859863.
  • 12
    Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001; 51: 151177.
  • 13
    Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? HIV Clin Trials 2003; 4: 193201.
  • 14
    Mocroft A, Youle M, Moore A et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment center. AIDS 2001; 15: 185194.
  • 15
    Bini T, Testa L, Chiesa E et al. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24: 115122.
  • 16
    Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naïve HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26: 191197.
  • 17
    Aminio Monforte A, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14: 499507.
  • 18
    Ghani AC, Henley W, Donnelly CA et al. Comparison of the effectiveness of non-nucloside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational database. AIDS 2001; 15: 11331142.
  • 19
    Ghani AC, Henley W, Anderson RM et al. Patterns of antiretroviral use in the United States of America: analysis of three observational databases. HIV Med 2003; 4: 2432.
  • 20
    Moorman AC, Holmberg SD, Marlowe SI et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV Outpatient Study (HOPS). Ann Epidemiol 1999; 9: 349357.
  • 21
    Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 3744.
  • 22
    Yuan Y, Hay JW, McCombs JS. Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care 2003; 9: 4556.
  • 23
    Allison PD. Survival Analysis Using the SAS System, A Practical Guide. Cary, NC, SAS Institute, 1995.
  • 24
    Phillips AN, Lee CA, Elford J et al. Serial CD4 counts and development of AIDS. Lancet 1991; 337: 389392.
  • 25
    Cozzi Lepri A, Katzenstein TL, Ulum H et al. The relative prognostic value of plasma HIV RNA levels and CD4 counts in advanced HIV infection. AIDS 1998; 12: 16391643.
  • 26
    Yerly S, Perneger TV, Hirschel B et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med 1998; 158: 247252.